Evaxion A (EVAX) Notes Payables (2023 - 2025)
Evaxion A (EVAX) posted Notes Payables of $1.1 million for Q2 2025, down 58.33% on a QoQ basis from $2.7 million in Q4 2023.
Evaxion A (EVAX) Notes Payables (2023 - 2025) Analysis & Trends
Evaxion A's Notes Payables history runs 2 years deep, the most recent figure standing at $1.1 million for Q2 2025.
- Quarterly Notes Payables changed N/A year-over-year to $1.1 million in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $1.1 million (changed N/A YoY) and the FY2023 annual result came in at $2.7 million, changed N/A from the prior year.
- Notes Payables was $1.1 million for Q2 2025 at Evaxion A, down from $2.7 million in the prior quarter.
- Across five years, Notes Payables topped out at $2.7 million in Q4 2023 and bottomed at $1.1 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Evaxion A | 1.23 Bn | 1.23 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 1.13 Mn |
| Dec 31, 2023 | 2.71 Mn |